Literature DB >> 17267304

Quantitative determination of the macrolide antibiotic tulathromycin in plasma and broncho-alveolar cells of foals using tandem mass spectrometry.

Eberhard Scheuch1, Janina Spieker, Monica Venner, Werner Siegmund.   

Abstract

The long-acting antibiotic tulathromycin is on the marked for treatment of pulmonary infection of cattle, swine and horses. To measure disposition and distribution of tulathromycin in foals, a high throughput method was developed for horse plasma (calibration range: 0.006-0.8 microg/mL) and broncho-alveolar cells (calibration range: 0.1-4.0 microg/10(9)cells) using tandem mass spectrometry. Tulathromycin was extracted from plasma and broncho-alveolar fluid using cation exchange cartridges with acetonitrile/ammonia (95:5, v/v). The chromatography was performed isocratically with a mobile phase consisting of 5 mM ammonium formiate buffer/acetonitrile (30:70, v/v). The mass spectrometer operated in selected ion mode with atmospheric pressure chemical ionization to monitor the respective MH+ ions m/z 577.3 for tulathromycin and m/z 679.3 for the internal standard roxithromycin. All quality parameters fulfilled the international criteria for bioanalytical method validation and were successfully applied to the determination of tulathromycin in plasma of foals and broncho-alveolar cells. In foals, tulathromycin after intramuscular administration was rapidly absorbed, widely distributed and slowly eliminated. It cumulated manifold in broncho-alveolar cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267304     DOI: 10.1016/j.jchromb.2006.12.034

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

2.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

3.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.